Markers/Short Reads


In a spate of proteomics mergers, Cambridge Antibody Technology swallowed up Oxford GlycoSciences in a £109.6 million all-stock deal, and Structural Bioinformatics emerged with the upper hand in its merger with San Diego neighbor GeneFormatics.


Lilly added more collaborations to its belt. The company is working with MDS Proteomics’ technology to study phosphorylated proteins, and with Molecular Staging’s platform to identify biomarkers for sepsis.


Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.